For subscribers
How AI helped one US man (and his brother) build a $2.3 billion company
Sign up now: Get ST's newsletters delivered to your inbox
Medvi founder Matthew Gallagher took just two months, US$20,000 (S$26,000) and more than a dozen AI tools to get his start-up off the ground.
PHOTO: MAGGIE SHANNON/NYTIMES
LOS ANGELES – Mr Matthew Gallagher took just two months, US$20,000 (S$26,000) and more than a dozen artificial intelligence tools to get his start-up off the ground.
From his house in Los Angeles, the 41-year-old used AI to write the code for the software that powers his company, produce the website copy, generate the images and videos for advertisements and handle customer service. He created AI systems to analyse his business’s performance. And he outsourced the other stuff he could not do himself.
His start-up, Medvi, a telehealth provider of GLP-1 weight-loss drugs, got 300 customers in its first month. In its second month, it gained 1,000 more. In 2025, Medvi’s first full year in business, the company generated US$401 million in sales.
Mr Gallagher then hired his only employee, his younger brother Elliot. In 2026, they are on track to do US$1.8 billion – or S$2.3 billion – in sales.
A US$1.8 billion company with just two employees? In the age of AI, it’s increasingly possible.
Mr Sam Altman, chief executive officer of OpenAI, predicted the rise of a new breed of super-efficient company in 2024. A one-person business worth US$1 billion “would have been unimaginable without AI”, he said on a podcast, “and now it will happen”.
Now as AI tools spread, entrepreneurs are harnessing the technology to expand their start-ups to an enormous scale at breathtaking speed with very few humans. Big companies, especially in tech, are getting in on the disruption, too. Pinterest, Block and others have cut thousands of workers in recent months, citing efficiencies enabled by AI.
Mr Gallagher, who formerly ran a start-up that sold wristwatches, said he thought Mr Altman’s prophecy of a one-person US$1 billion company would be a firm that built AI. He was excited when he realised he may have done it, taking an old idea – being a middleman for weight-loss drugs – and using AI to turbocharge it.
“It’s not an AI company, but I did it with AI,” he said.
In an e-mail, Mr Altman said that it appeared he had won a bet with his tech CEO friends over when such a company would appear, and that he “would like to meet the guy” who had done it.
Medvi is technically not a one-person US$1 billion company, since Mr Gallagher hired his brother and has some contractors. The start-up, which has not raised outside funding, also has no official valuation. But many highly valued tech companies can only dream of hitting US$1 billion in revenue with so few workers. Medvi is also profitable, Mr Gallagher said.
The New York Times was given access to Medvi’s financials to verify its revenue and profits and interviewed Mr Gallagher’s business partners.
On a recent afternoon at the Soho House club in Los Angeles, Mr Gallagher, sporting unkempt curly hair, a baggy T-shirt and tattoos on his arms and hands, said the last 18 months had been a whirlwind.
He works on Medvi from his house basically any time he is not showering, sleeping or spending time with his two children, he said during a two-hour conversation. He even made an AI clone of his voice to help manage his personal life, using it to call and schedule appointments so he would have more time to work.
Not everyone can build such an AI-enabled company, though many may try. Mr Gallagher is suited to the moment because he knows marketing and how to use cutting-edge AI, said Mr Kobie Fuller, an investor at venture capital firm Upfront Ventures who has advised him.
“Those folks that have those skills, it’s kind of like their superpower,” Mr Fuller said. “This is an extreme example, but I don’t think it’s going to be the last by any stretch.”
Mr Gallagher has told hardly anyone about his company, which he said was raking in more than US$3 million a day. He was nervous to talk publicly about it, he said.
“I mean, it’s crazy, right?” he asked, before answering himself. “It’s crazy.”
Spotting opportunity
Mr Gallagher had an itinerant childhood, living out of motels and cars for a time before landing in Cincinnati when he was 12. That was where his uncle gave him a laptop, which he used to teach himself to code so he could make a Weird Al Yankovic fan page.
As a teenager, Mr Gallagher began building websites for local businesses. He always had a hustle, including selling candles and samurai swords on eBay. At 18, after building a web hosting business, he sold it for US$6,000.
Mr Gallagher briefly attended the University of Cincinnati and Northern Kentucky University but did not graduate. In 2010, he moved to Los Angeles to become an actor. He eventually returned to coding, bouncing between tech jobs.
In 2016, he built Watch Gang, a start-up that sold wristwatches via subscription. It had fans but never turned a profit, even as Mr Gallagher chased revenue growth and hired 60 people.
OpenAI’s release of ChatGPT in 2022 inspired Mr Gallagher to start tinkering with AI. Two years later, he met Dr Jiten Chhabra, a co-founder of CareValidate, a medical start-up in Atlanta.
CareValidate offers what is essentially a telehealth-in-a-box kit. Companies, employers or retailers that want to sell customers prescription drugs can use CareValidate’s technology and network of online doctors to set up a business. The company’s software connects patients with doctors and pharmacies, which write, fulfil and ship the prescriptions. CareValidate charges fees for its software.
Mr Gallagher saw an opportunity for his own telehealth business. He could use AI to do the branding and marketing and let CareValidate and a similar platform, OpenLoop Health, handle the doctors, pharmacies, shipping and compliance. He planned to start with GLP-1s.
He was entering an established market. For nearly a decade, Hims & Hers Health, Ro and other companies have sold drugs for erectile dysfunction and hair loss online, using an online network of doctors to write the prescriptions. Hims, which went public in 2021, has 2,442 employees and generated US$2.4 billion in revenue in 2025.
Hims and Ro had already expanded into GLP-1 drugs, but Mr Gallagher thought he could do the same thing faster and more efficiently with AI and the doctor-on-demand platforms.
He used many AI tools to build Medvi’s website, including ChatGPT, Claude and Grok. He created custom tools, including AI agents, or bots that perform tasks on their own, to get his software systems to communicate with one another. He tested AI voice tools from ElevenLabs and others for communicating with customers. And he used image and video generators Midjourney and Runway to create media for his website and ads.
Altogether, he spent US$20,000 on the software and the first month of marketing.
Medvi’s initial website featured photos of smiling models who looked AI-generated and before-and-after weight-loss photos from around the web with the faces changed. Some of its ads were AI slop. A scrolling ticker of mainstream media logos made it look as if Medvi had been featured in Bloomberg and the Times when it had merely advertised there.
But Mr Gallagher was most concerned with getting Medvi’s checkout to work smoothly and making sure his AI customer service system stuck to the task at hand. He tested it by asking the system for lasagna recipes; it took some tweaking to get it to stop supplying them, he said.
Medvi opened for business in September 2024. It was perfectly timed. Americans wanted cheap GLP-1s, delivered without going to a doctor’s office. The start-up charged as little as US$179 for the first month’s supply of the drugs, in line with competitors.
The sky’s the limit?
From the beginning, “growth was insane”, Mr Gallagher said.
Medvi quickly became one of CareValidate’s and OpenLoop’s top clients. The companies said they were blown away by the start-up’s speed and scale.
“You’re like, ‘Do you have an army of people behind you somewhere?’ And he’s like, ‘Nope’,” CareValidate’s Dr Chhabra said of Mr Gallagher.
Dr Jon Lensing, OpenLoop’s CEO, said Mr Gallagher had started sharing tech tips with his company. “Matthew’s native tongue seems to be AI,” he said.
There were snags. Medvi’s customer service chatbot sometimes made up prices for the drugs. (Mr Gallagher honoured those.) Or it hallucinated, claiming Medvi sold hair-loss drugs when it did not.
If customers wanted to talk to a person, Medvi’s customer service chatbot had been trained to transfer them to Mr Gallagher’s cellphone. That led to more than 1,000 customer service calls, he recalled.
To manage the onslaught, he integrated programs from OpenLoop and CareValidate that fielded customer service calls. Mr Gallagher soon graduated from using online legal site LegalZoom to using a law firm, and from using AI accounting tools to using an accounting firm. He also hired media agencies to help buy ads to entice customers.
As sales took off, Mr Gallagher asked Mr Fuller, the venture capital investor, if he should raise venture funding. Mr Fuller told him that if he did not need the money, he should not raise it.
“You should just keep building,” Mr Fuller said he had told Mr Gallagher. Mr Gallagher later thanked him for the advice.
In March 2025, Mr Gallagher changed something minor on Medvi’s website and then went on a hike. From the trail, he got a call from one of his media agencies asking whether it was odd that there had been no orders for the last hour.
Mr Gallagher realised that his update must have broken something. With no one to fix it, he sprinted home. The downtime lost him around 200 potential customers, he said.
Still, he was hesitant to hire anybody. At Watch Gang, having 60 employees had not helped the company grow. “It just increased my costs, and then it delayed my decision-making because I had more people to deal with,” he said. Medvi’s biggest advantage was his ability to move quickly, he said.
Mr Gallagher added two engineers on contract and decided to hire only his 36-year-old brother in Cincinnati in April. His brother’s job includes intercepting and filtering communication, so Mr Gallagher can focus on his priorities.
“I just helped take a lot of the weight off of him,” Mr Elliot Gallagher said in an interview.
That gave Mr Matthew Gallagher breathing room to fix some shortcuts he had initially taken, like swopping out the before-and-after weight-loss photos for ones from real customers. Some photos on Medvi’s homepage remain AI-generated.
By the end of 2025, Medvi had reached US$401 million in annual sales and amassed 250,000 customers. It produced 16.2 per cent in net profit, or US$65 million, with spending going to the fees for telehealth platforms, marketing and then software. Hims, by contrast, had a net profit of 5.5 per cent in 2025.
Mr Gallagher is reinvesting some of Medvi’s profits into expansion. He considered buying companies that provide other health products, but decided it was just as easy to build them himself.
In February, Medvi started selling men’s health products, including erectile dysfunction drugs. That business hit 50,000 customers in the first month, and is on track to eclipse the GLP-1 business in four months, Mr Gallagher said.
In March, Medvi added healthy meal delivery plans, which OpenLoop handles. Next up is women’s health, including hormone therapy drugs. Hair-growth drugs, supplements and skincare products are also on the agenda.
Medvi’s total profit of US$70 million to US$80 million so far has made Mr Gallagher emotional, given his upbringing.
“For the first time, I’m not in survival mode,” he said.
In 2025, he set up a foundation with US$1 million and donated to a Los Angeles cat rescue organisation, with plans to also donate to a non-profit that helps young people experiencing homelessness. His goal is to run most of Medvi’s profits through the foundation. For fun, he invests in films and buys historical items, including a pocket watch from the 1700s.
Mr Gallagher does not anticipate hiring more people. He said he just did not see how it would help Medvi, though he misses the camaraderie of colleagues. “At this point, I kind of want to hire people because I’m lonely,” he said.
But some human touch is still needed.
In September 2025, Medvi began assigning human account managers to a subset of customers. When those customers call, text or e-mail with a question, they connect to the same account manager. The idea is that the account managers will get to know clients and remember details such as birthdays or children’s names, creating higher customer satisfaction.
Medvi’s seven account managers, all hired on contract, now have several hundred clients each. To manage that many relationships, they are using AI. NYTIMES


